{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:52:02Z","timestamp":1790988722462,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":4147,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100015606","name":"Wyeth Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015606","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1093\/annonc\/mdn066","type":"journal-article","created":{"date-parts":[[2008,4,2]],"date-time":"2008-04-02T20:44:48Z","timestamp":1207169088000},"page":"1387-1392","source":"Crossref","is-referenced-by-count":146,"title":["Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features"],"prefix":"10.1016","volume":"19","author":[{"given":"J.","family":"Bellmunt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Szczylik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Feingold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Strahs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Berkenblit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdn066_bb0010","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1128\/MCB.24.1.200-216.2004","article-title":"mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1\/eukaryotic translation initiation factor 4E","volume":"24","author":"Fingar","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1093\/annonc\/mdn066_bb0015","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1128\/MCB.22.20.7004-7014.2002","article-title":"Regulation of hypoxia-inducible factor 1\u03b1 expression and function by the mammalian target of rapamycin","volume":"22","author":"Hudson","year":"2002","journal-title":"Mol Cell Biol"},{"key":"10.1093\/annonc\/mdn066_bb0020","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0092-8674(00)00117-3","article-title":"TOR, a central controller of cell growth","volume":"103","author":"Schmelzle","year":"2000","journal-title":"Cell"},{"key":"10.1093\/annonc\/mdn066_bb0025","first-page":"3749S","article-title":"Design, synthesis and biological evaluation of C-42 hydroxyesters of rapamycin: the identification of CCI-779 [abstract]","volume":"7","author":"Skotnicki","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdn066_bb0030","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1158\/1078-0432.CCR-06-2798","article-title":"The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy","volume":"13","author":"Abraham","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdn066_bb0035","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1158\/0008-5472.CAN-05-2825","article-title":"Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus","volume":"66","author":"DelBufalo","year":"2006","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdn066_bb0040","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdn066_bb0045","article-title":"Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon-\u03b1 (IFN) or the combination of IFN + TEMSR [abstract]","volume":"25","author":"Parasuraman","year":"2007","journal-title":"J Clin Oncol, ASCO Annual Meeting Proceedings Part I"},{"issue":"Suppl 9","key":"10.1093\/annonc\/mdn066_bb0050","doi-asserted-by":"crossref","first-page":"ix87","DOI":"10.1093\/annonc\/mdm299","article-title":"Temsirolimus in the treatment of advanced renal cell carcinoma","volume":"18","author":"Gore","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdn066_bb0055","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn066_bb0060","series-title":"Torisel [Package Insert]","year":"2007"},{"key":"10.1093\/annonc\/mdn066_bb0065","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.ejca.2006.03.015","article-title":"Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus","volume":"42","author":"Duran","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdn066_bb0070","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1200\/JCO.2004.08.116","article-title":"Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer","volume":"22","author":"Raymond","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn066_bb0075","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.clpt.2004.08.025","article-title":"Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer","volume":"77","author":"Boni","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1093\/annonc\/mdn066_bb0080","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/01.ftd.0000245377.93401.39","article-title":"Sirolimus\u2014challenging current perspectives","volume":"28","author":"Buhaescu","year":"2006","journal-title":"Ther Drug Monit"},{"key":"10.1093\/annonc\/mdn066_bb0085","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/01.tp.0000235545.49391.1b","article-title":"Sirolimus interferes with iron homeostasis in renal transplant recipients","volume":"82","author":"Maiorano","year":"2006","journal-title":"Transplantation"},{"key":"10.1093\/annonc\/mdn066_bb0090","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1016\/j.transproceed.2007.06.032","article-title":"Study of anemia after late introduction of everolimus in the immunosuppressive treatment of renal transplant patients","volume":"39","author":"Sanchez Fructuoso","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1093\/annonc\/mdn066_bb0095","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2165\/00003495-200767030-00004","article-title":"Use of sirolimus in solid organ transplantation","volume":"67","author":"Augustine","year":"2007","journal-title":"Drugs"},{"key":"10.1093\/annonc\/mdn066_bb0100","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00002018-200629120-00006","article-title":"Sirolimus-associated proteinuria and renal dysfunction","volume":"29","author":"Rangan","year":"2006","journal-title":"Drug Saf"},{"key":"10.1093\/annonc\/mdn066_bb0105","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.transproceed.2007.07.060","article-title":"Impact on renal function of the use of sirolimus in cardiac transplantation","volume":"39","author":"Ubilla","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1093\/annonc\/mdn066_bb0110","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdn066_bb0115","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419402445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419402445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/19\/8\/1387\/624706\/mdn066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T04:41:07Z","timestamp":1624423267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419402445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["S0923753419402445"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdn066","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}